CORD-19:3c1f47a07aaf0e393dee9fbd08596a4b9f4f0a03 / 323988-324309
Annnotations
CORD-19-Sentences
{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T2484","span":{"begin":0,"end":321},"obj":"Sentence"},{"id":"T39872","span":{"begin":0,"end":321},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The data from the 2005 survey confirmed the high resistance rates for AMP (96% vs. 95%), SXT (94% vs. 94%), TET (93% vs. 93%) and CHL (69% vs. 70%) observed in the baseline study, and showed a remarkably increase in the resistance rates to quinolones (57% vs. 35% for NAL and 33% vs. 18% for CIP) and CRO (1.7% vs. 0.1%)."}
CORD-19_Custom_license_subset
{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T220","span":{"begin":0,"end":321},"obj":"Sentence"}],"text":"The data from the 2005 survey confirmed the high resistance rates for AMP (96% vs. 95%), SXT (94% vs. 94%), TET (93% vs. 93%) and CHL (69% vs. 70%) observed in the baseline study, and showed a remarkably increase in the resistance rates to quinolones (57% vs. 35% for NAL and 33% vs. 18% for CIP) and CRO (1.7% vs. 0.1%)."}
CORD-19-PD-MONDO
{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1112","span":{"begin":292,"end":295},"obj":"Disease"},{"id":"T91316","span":{"begin":292,"end":295},"obj":"Disease"}],"attributes":[{"id":"A1112","pred":"mondo_id","subj":"T1112","obj":"http://purl.obolibrary.org/obo/MONDO_0009459"},{"id":"A1113","pred":"mondo_id","subj":"T1112","obj":"http://purl.obolibrary.org/obo/MONDO_0015364"},{"id":"A38975","pred":"mondo_id","subj":"T91316","obj":"http://purl.obolibrary.org/obo/MONDO_0009459"},{"id":"A49155","pred":"mondo_id","subj":"T91316","obj":"http://purl.obolibrary.org/obo/MONDO_0015364"}],"text":"The data from the 2005 survey confirmed the high resistance rates for AMP (96% vs. 95%), SXT (94% vs. 94%), TET (93% vs. 93%) and CHL (69% vs. 70%) observed in the baseline study, and showed a remarkably increase in the resistance rates to quinolones (57% vs. 35% for NAL and 33% vs. 18% for CIP) and CRO (1.7% vs. 0.1%)."}